Notes to the Financial Statements Note 18: Detailed Information – People Costs continued (b) Share-based payments Long Term Incentives A face value equity allocation methodology, being a five day volume weighted average share price based on the market price of a CSL share at the time of grant, is used to determine the number of units granted to a participant under each of the shared based payment plans, which are as follows: • The Executive Performance and Alignment Plan (EPA) grants Performance Share Units (PSU) to qualifying executives. Vesting is subject to continuing employment, satisfactory performance and the achievement of absolute return measures. The return measures include EPS growth and seven-year average Return on Invested Capital (ROIC). • The Retain and Grow Plan (RGP) grants Restricted Share Units (RSU) to qualifying employees, participation in the RGP plan is broader than in the EPA plan. Vesting is subject to continuing employment and satisfactory performance. EPA and RGP grants made prior to 1 September 2021 vest in equal tranches on the first, second, third and fourth anniversaries of the grant. EPA grants made from 1 September 2021 vest on the third anniversary. RGP grants made from 1 September 2021 vest in equal tranches on the first, second and third anniversaries of the grant. For EPA and RGP commencement benefit awards, vesting dates will vary. There have been no changes to the grant terms of any existing instruments. The fair value of the awards granted is estimated at the date of grant using an adjusted form of the Black-Scholes model, considering the terms and conditions upon which the PSUs and RSUs were granted. There is no exercise price payable on PSUs and RSUs. The following grants were issued during the year ended 30 June 2023: Date of grant PSUs RSUs 1 September 2022 411 781,314 1 November 2022 210,065 – 1 March 2023 5,779 121,093 The relevant tranche of PSUs will exercise upon vesting between September 2024 and September 2025. The relevant tranche of RSUs will exercise upon vesting between September 2023 and September 2025. The Non-Executive Directors Plan The Non-Executive Directors (NED) pay a minimum of 20% of their pre-tax base fee in return for a grant of rights, each right entitling a NED to acquire one CSL share at no cost (shares purchased on market). There is a nominated restriction period of three to fifteen years, after which the NED will have access to their shares. On 25 August 2022, 3,135 rights were granted under the NED Rights Plan with vesting through to August 2023. Global Employee Share Plan The Global Employee Share Plan (GESP) allows employees to make contributions from post-tax salary up to a maximum of A$12,000 (or equivalent) per six month contribution period. Employees receive shares at a 15% discount to the applicable market rate over the five day period up to and including the first and last ASX trading days of the six month period, whichever is the lower. Recognition and measurement The fair value of awards granted are recognised as an employee benefit expense with a corresponding increase in equity. Fair value is independently measured at grant date and recognised over the period during which the employees become unconditionally entitled to the award. Fair value is independently determined using a combination of the Binomial and Black-Scholes valuation methodologies, including Monte Carlo simulation, considering the terms and conditions on which the awards were granted. The fair value of the awards granted excludes the impact of any non-market vesting conditions, which are included in assumptions about the number of awards that are expected to vest. At each reporting date, the number of awards that are expected to vest is revised. The employee benefit expense recognised each period considers the most recent estimate of the number of awards that are expected to vest. No expense is recognised for awards that do not ultimately vest, except where the vesting is conditional upon a market condition and that market condition is not met. The Group does not have any awards with a market condition as at 30 June 2023. CSL Limited Annual Report 2022/23 154
RkJQdWJsaXNoZXIy MjE2NDg3